Discovery of novel β-carboline/melatonin hybrids as STAT3 inhibitors for the treatment of lung cancer via increasing DNA damage

This publication has 33 references indexed in Scilit:

• WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin
  Biochemical Pharmacology, 2024
• Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
  Clinical Lung Cancer, 2022
• Structural hybridization as a facile approach to new drug candidates
  Bioorganic & Medicinal Chemistry Letters, 2020
• Melatonin modulates airway smooth muscle cell phenotype by targeting the STAT3/Akt/GSK-3β pathway in experimental asthma
  Cell and tissue research, 2019
• Activated STAT3 may participate in tumor progression through increasing CD133/survivin expression in early stage of colon cancer
  Biochemical and Biophysical Research Communications, 2018
• Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor
  Drugs, 2017
• Spectroscopic and structural studies on the interaction of an anticancer β–carboline alkaloid, harmine with GC and AT specific DNA oligonucleotides
  Chemico-Biological Interactions, 2016
• Constitutive activation of STAT3 in breast cancer cells: A review
  International Journal of Cancer, 2015
• STAT3 regulated ATR via microRNA-383 to control DNA damage to affect apoptosis in A431 cells
  Cellular Signalling, 2015
• Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors
  European Journal of Medicinal Chemistry, 2015